This inventor holds 13 USPTO granted patents and 16 published patent applications and 4 EPO patents, primarily in Immunotherapy Development. Top assignees: Immatics Biotechnologies Gmbh, Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet, Synimmune Gmbh. Active years: 2015-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Tuebingen, DE (2015 - 2024)
- Tübingen, DE (2024)
Company Filing History:
10 out of 728 
2 out of 16 
1 out of 2 Years Active: 2015-2026
Areas of Expertise:
Title: Martin Hofmann: Innovator in Antigen Binding Proteins
Introduction
Martin Hofmann is a distinguished inventor based in Tuebingen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding proteins. With a total of 10 patents to his name, Hofmann's work focuses on innovative solutions for cancer diagnosis and treatment.
Latest Patents
Hofmann's latest patents include groundbreaking inventions such as antigen binding proteins specifically targeting melanoma-associated antigen A (MAGE-A). This invention provides proteins that bind to MAGE-A antigenic peptides in complex with major histocompatibility (MHC) proteins. These proteins are crucial for diagnosing, treating, and preventing MAGE-A expressing cancers. Another notable patent is the BMA031 antigen binding polypeptide, which specifically binds to the α/β T cell receptor (TCR)/cluster of differentiation 3 (CD3) complex. This invention also includes nucleic acids and vectors that encode the antigen binding polypeptide, as well as pharmaceutical compositions for medical applications.
Career Highlights
Throughout his career, Martin Hofmann has worked with prominent companies in the biotechnology sector, including Immatics Biotechnologies GmbH and Synimmune GmbH. His innovative research has positioned him as a key figure in the development of therapeutic solutions for proliferative diseases.
Collaborations
Hofmann has collaborated with notable colleagues such as Felix Unverdorben and Sebastian Bunk. These partnerships have further enhanced his research and contributions to the field.
Conclusion
Martin Hofmann's work in the development of antigen binding proteins represents a significant advancement in cancer treatment and diagnosis. His innovative patents and collaborations continue to impact the biotechnology landscape positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile